Insmed Incorporated (Insmed) is a biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases and endocrine disorders within niche markets that have unmet medical needs. The Company's development and commercial activities involve drugs that modulate Insulin-like Growth Factor-1 (IGF-1) activity in the human body. Insmed's lead product, IPLEX (mecasermin rinfabate injection), is approved by the United States Food and Drug Administration (FDA) as a once-daily IGF-1 replacement therapy. In addition to its IPLEX development and commercialization programs, Insmed has an oncology program focused on two compounds, INSM-18 and rhIGFBP-3.

http://finance.google.com/finance?q=INSM